At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Trading 07-02 09:54:31 EDT
1.47
+0.04
+2.80%
High1.47Low1.45Vol29.24K
Open1.45D1 Closing1.43Amplitude1.41%
Mkt Cap89.19MTradable Cap81.77MTotal Shares60.67M
T/O42.79KT/O Rate0.05%Tradable Shares55.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer
THOMSON REUTERS  ·  06-25
Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
GlobeNewswire  ·  06-25
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial
Reuters  ·  06-18
Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial
Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
THOMSON REUTERS  ·  06-18
Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference
Deep News  ·  06-11
Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference
Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion
Reuters  ·  06-10
Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion
Maia Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 Thio-101 Expansion Trial
THOMSON REUTERS  ·  06-10
Maia Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 Thio-101 Expansion Trial
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
GlobeNewswire  ·  06-10
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
TIPRANKS  ·  06-04
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial
Reuters  ·  06-04
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial
Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
THOMSON REUTERS  ·  06-04
Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study
MT Newswires Live  ·  06-03
MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study
MAIA Biotechnology receives FDA clearance for amendment to IND application
TIPRANKS  ·  06-03
MAIA Biotechnology receives FDA clearance for amendment to IND application
Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion
THOMSON REUTERS  ·  06-03
Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion
MAIA Biotechnology announces open market purchases by CEO, director
TIPRANKS  ·  06-02
MAIA Biotechnology announces open market purchases by CEO, director
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)
TIPRANKS  ·  06-02
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)
MAIA says directors, officers hold 20.46% beneficial stake
Reuters  ·  06-02
MAIA says directors, officers hold 20.46% beneficial stake
Maia Biotechnology Announces Open Market Purchases by CEO and Director
THOMSON REUTERS  ·  06-02
Maia Biotechnology Announces Open Market Purchases by CEO and Director
Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29
Reuters  ·  06-02
Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29
Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200
Reuters  ·  06-02
Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--